Cardarine
Also known as: gw501516, gw-501516, gw 501516, endurobol, PPARδ agonist cardarine
PPARδ agonist studied for endurance enhancement and lipid metabolism (note: associated with cancer risk in animal studies).
Quick Reference
Cardarine - Research Images
PSO vial render · Scientific images from Wikipedia · Tap to enlarge
Overview
Abandoned metabolic and cardiovascular drug
GW501516 is a PPARδ receptor agonist that was invented in a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s. It entered into clinical development as a drug candidate for metabolic and cardiovascular diseases, but was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several organs.
Mechanism of Action
GW501516 is a PPARδ receptor agonist that was invented in a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s. It entered into clinical development as a drug candidate for metabolic and cardiovascular diseases, but was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several organs.
What Researchers Are Saying
Community Reports - Not Medical Advice
The following is aggregated from public forums, Reddit, and research communities. These are anecdotal reports from researchers only - not verified clinical data and not a recommendation of any kind.
Cardarine (also known as gw501516, gw-501516) is studied within the selective androgen receptor research community. PPARδ agonist studied for endurance enhancement and lipid metabolism (note: associated with cancer risk in animal studies).
Last updated October 28, 2026
Research status: limited. Cardarine appears across selective androgen receptor research forums and academic literature. Researchers note this compound falls in the sarms category.
Last updated October 28, 2026
What Do You Think of This Peptide?
Share your opinion or research experience with Cardarine. Comments are reviewed before appearing.